Zobrazeno 1 - 10
of 41
pro vyhledávání: '"M. B. Fowler"'
Autor:
M. B. Fowler
Publikováno v:
Journal of the Geological Society. 149:209-220
Elemental, radiogenic isotope (Sr, Nd) and stable isotope (O) data from samples of the 456 Ma Caledonian Glen Dessarry syenite are all compatible with a two-stage crystal-fractionation model for the evolution of the magmas, locally modified by contam
Autor:
F. WAAGSTEIN, M. R. BRISTOW, K. SWEDBERG, F. CAMERINI, M. B. FOWLER FOR THE METROPROLOL IN DILATED CARDIOMYOPATHY MDC TRIAL STUDY GROUP IN ITALIA F. CAMERINI, A. DI LENARDA, G. LARDIERI, L. MESTRONI, M. D'AVANZO, SINAGRA, GIANFRANCO
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::aa842f4845bd72a003268c5c4747e8bc
http://hdl.handle.net/11368/1700789
http://hdl.handle.net/11368/1700789
Autor:
C V, Leier, M A, Silver, B M, Massie, J B, Young, M B, Fowler, H O, Ventura, R E, Hershberger
Publikováno v:
Congestive heart failure (Greenwich, Conn.). 7(5)
Autor:
C V, Leier, J B, Young, T B, Levine, I, Pina, P W, Armstrong, M B, Fowler, L, Warner-Stevenson, J N, Cohn, J B, O'Connell, M R, Bristow, J M, Nicklas, D E, Johnstone, J, Howlett, H O, Ventura, T D, Giles, B H, Greenberg, K, Chatterjee, R C, Bourge, C W, Yancy, S S, Gottleib
Publikováno v:
Congestive heart failure (Greenwich, Conn.). 7(6)
Autor:
M B, Fowler, M, Vera-Llonch, G, Oster, M R, Bristow, J N, Cohn, W S, Colucci, E M, Gilbert, M A, Lukas, M J, Lacey, R, Richner, S T, Young, M, Packer
Publikováno v:
Journal of the American College of Cardiology. 37(6)
Carvedilol reduces disease progression in heart failure, but to our knowledge, its effects on hospitalizations and costs have not been evaluated.We examined the effects on hospitalization frequency and costs in the U.S. Carvedilol Heart Failure Trial
Autor:
M. B. Fowler
Publikováno v:
Prevention of Disease Progression Throughout the Cardiovascular Continuum ISBN: 9783642625671
Since the first open-label studies demonstrating the benefit of s-blockade in heart failure were reported in Sweden in the 1970s [1–3], a number of double-blind, placebo-controlled studies involving more than 10,000 patients have confirmed the bene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c77664c464d8750927153ff124a69f6c
https://doi.org/10.1007/978-3-642-56525-0_7
https://doi.org/10.1007/978-3-642-56525-0_7
Autor:
M B, Fowler
Publikováno v:
European heart journal. 19
Heart failure is a common clinical problem in patients with cardiovascular disease. Mortality remains high despite conventional therapy. The morbidity associated with heart failure accounts for numerous hospitalizations and significant health care ex
Publikováno v:
Catheterization and cardiovascular diagnosis. 43(4)
Assumed oxygen consumption (VO2) is increasingly used as a convenient surrogate for measured VO2 for calculation of cardiac output. This substitution is often based on empirical formulae, previously validated only in relatively young patients. To ass
Autor:
J N, Cohn, M B, Fowler, M R, Bristow, W S, Colucci, E M, Gilbert, V, Kinhal, S K, Krueger, T, Lejemtel, K A, Narahara, M, Packer, S T, Young, T L, Holcslaw, M A, Lukas
Publikováno v:
Journal of cardiac failure. 3(3)
Many patients remain markedly symptomatic despite optimal current therapy for heart failure. Beta-blockers have often been viewed as contraindicated in this group because of their potential adverse short-term effects on cardiac function.One hundred t
Autor:
M R, Bristow, E M, Gilbert, W T, Abraham, K F, Adams, M B, Fowler, R E, Hershberger, S H, Kubo, K A, Narahara, H, Ingersoll, S, Krueger, S, Young, N, Shusterman
Publikováno v:
Circulation. 94(11)
We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure.Three hundred forty-five subjects with m